{
  "id": "63ddbe649da0d561",
  "title": "BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle ( SPV ) Transaction to Advance Ozuriftamab Vedotin ( Oz - V ) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma ( OPSCC ) ",
  "description": "20251231T123000Z",
  "content": "",
  "source": "marketscreener.com",
  "source_url": "https://www.marketscreener.com/news/bioatla-and-gatc-health-announce-a-40-million-special-purpose-vehicle-spv-transaction-to-advance-ce7e59d8df8cf322",
  "published_at": "20251231T123000Z",
  "fetched_at": "2026-01-01T00:26:23.010909+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [],
  "location": "",
  "raw_data": {
    "url": "https://www.marketscreener.com/news/bioatla-and-gatc-health-announce-a-40-million-special-purpose-vehicle-spv-transaction-to-advance-ce7e59d8df8cf322",
    "url_mobile": "",
    "title": "BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle ( SPV ) Transaction to Advance Ozuriftamab Vedotin ( Oz - V ) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma ( OPSCC ) ",
    "seendate": "20251231T123000Z",
    "socialimage": "https://www.marketscreener.com/images/twitter_MS_fdnoir.png",
    "domain": "marketscreener.com",
    "language": "English",
    "sourcecountry": ""
  }
}